[Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life].
The efficacy and QOL in a cancer pain patient who converted to transdermal fentanyl from low-dose morphine (n=5) or high-dose morphine (n=5) were retrospectively compared. Cancer pain control was evaluated by visual analogue scales (VAS) score. Patients switched from low-dose morphine demonstrated significantly better scales. The number of morphine rescues was also significantly less in the low-dose conversion group. In conclusion, conversion from low-dose morphine is useful for cancer pain control from the aspect of efficacy and QOL.
Yamazaki
Masumi
M
Hospital Pharmacy, Tokyo Medical University.
Aoki
Tatsuya
T
Tachibana
Masaaki
M
Akashi
Takao
T
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000698:Analgesia; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage*; D009369:Neoplasms / Q000503:physiopathology / Q000523:psychology; D010148:Intractable Pain / Q000188:drug therapy*; D011788:Quality of Life; D012189:Retrospective Studies
D000701:Analgesics, Opioid; D009020:Morphine; D005283:Fentanyl